MaxCyte®, Inc., a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces data to be presented at the Keystone Symposia on Precision Genome Engineering summarizing in vitro and long-term preclinical toxicity and engraftment studies following targeted gene correction aimed at reversing mutations to wild-type sequence at clinically relevant levels in CD34+ hematopoietic stem cells (HSC) obtained from individuals with X-CGD. The oral and poster presentations will highlight use of MaxCyte’s proprietary, cGMP-compliant delivery platform in development of ex vivo gene-corrected cell therapies as a potential treatment for monogenic diseases. The Symposia is taking place January 8 to 12, 2017 in Breckenridge, Colorado.